When combined with an equally low dose of HDAd expressing IL-12p70, anti–PD-L1 antibody, and HSVtk safety switch, this ultralow-dose combination OAd/HDAd therapy modulated local and systemic immune activity, leading to partial and complete tumor responses in both preclinical studies and humans. This evidence concerns the gene CD274 and neoplasm.